1. Home
  2. GLTO

GLTO

Galecto Inc.

Logo Galecto Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 2:33pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Founded: 2011 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 18.5M IPO Year: 2020
Target Price: $7.00 AVG Volume (30 days): 230.7K
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.44 EPS Growth: N/A
52 Week Low/High: $0.50 - $3.70 Next Earning Date: 04-30-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: